| 嵌合抗原受体T细胞免疫疗法治疗儿童恶性肿瘤的研究进展 |
| |
| 引用本文： | 杨逸成,骆玥君,梁广华,梁颖君,邹子元,熊长明.嵌合抗原受体T细胞免疫疗法治疗儿童恶性肿瘤的研究进展[J].中国肿瘤临床,2019,46(24):1286-1291. |
| |
| 作者姓名： | 杨逸成 骆玥君 梁广华 梁颖君 邹子元 熊长明 |
| |
| 作者单位： | ①.中国医学科学院北京协和医学院阜外医院心内科(北京市 100037) |
| |
| 摘 要： | 嵌合抗原受体T细胞免疫疗法（CAR-T细胞疗法）是一种肿瘤免疫治疗方法，通过诱导T细胞的活化特异性识别肿瘤的靶点，释放细胞因子，发挥T细胞对肿瘤细胞的杀伤作用，可在共刺激因子协助下发挥持续的抗肿瘤作用。白血病、淋巴瘤等血液系统恶性肿瘤和神经母细胞瘤好发于儿童，具有较高的致死率，目前对于难治性和复发性肿瘤仍缺乏有效的治疗手段。随着CAR-T细胞疗法的研究深入，人们发现该法对上述儿童好发恶性肿瘤的治疗可发挥重要作用，对其难治性和复发性的病例也具有较好的疗效。本文将对CAR-T细胞疗法治疗儿童好发恶性肿瘤的相关研究进展进行综述。
|
| 关 键 词： | 嵌合抗原受体T细胞免疫疗法 儿童肿瘤 细胞因子释放综合征 神经毒性 |
| 收稿时间： | 2019-09-17 |
Progress in studies on chimeric antigen receptor-engineered T-cells for the treatment of pediatric cancers |
| |
| Affiliation: | ①.Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China②.Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China③.The First Clinical Medicine College, Southern Medical University, Guangzhou 510515, China |
| |
| Abstract: | Chimeric antigen receptor (CAR)-engineered T-cell therapy is a type of tumor immunotherapy. CAR T-cells recognize target sites on the tumor and are activated to release cytokines and to exert the T-cells' killing effect on tumor cells. It also makes use of costimulatory factors to assist these T-cells in exerting a sustained anti-tumor effect. Hematologic malignancies and neuroblastomas are prevalent among children. However, effective treatment for refractory and recurrent pediatric cancers is currently lacking. CAR T-cell therapy has been found to play an important role in the treatment of tumors that arise preferentially in children and has a good effect on the treatment of refractory and recurrent tumors. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
